These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2559 related articles for article (PubMed ID: 28057034)
21. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy? Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495 [TBL] [Abstract][Full Text] [Related]
22. The utility of Guo R; Yan W; Wang F; Su H; Meng X; Xie Q; Zhao W; Yang Z; Li N Cancer Imaging; 2024 Sep; 24(1):120. PubMed ID: 39256860 [TBL] [Abstract][Full Text] [Related]
23. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy. Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523 [TBL] [Abstract][Full Text] [Related]
24. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719 [TBL] [Abstract][Full Text] [Related]
25. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival. Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069 [TBL] [Abstract][Full Text] [Related]
26. Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer. Shang J; Ling X; Zhang L; Tang Y; Xiao Z; Cheng Y; Guo B; Gong J; Huang L; Xu H Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1945-53. PubMed ID: 27236466 [TBL] [Abstract][Full Text] [Related]
27. Prognostic Significance of FDG Uptake of Bone Marrow on PET/CT in Patients With Non-Small-Cell Lung Cancer After Curative Surgical Resection. Lee JW; Na JO; Kang DY; Lee SY; Lee SM Clin Lung Cancer; 2017 Mar; 18(2):198-206. PubMed ID: 27495385 [TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer. Oh D; Lee JE; Huh SJ; Park W; Nam H; Choi JY; Kim BT Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):549-54. PubMed ID: 24074928 [TBL] [Abstract][Full Text] [Related]
30. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866 [TBL] [Abstract][Full Text] [Related]
31. ¹⁸F-FDG PET-CT during chemo-radiotherapy in patients with non-small cell lung cancer: the early metabolic response correlates with the delivered radiation dose. Massaccesi M; Calcagni ML; Spitilli MG; Cocciolillo F; Pelligrò F; Bonomo L; Valentini V; Giordano A Radiat Oncol; 2012 Jul; 7():106. PubMed ID: 22781363 [TBL] [Abstract][Full Text] [Related]
32. The Role of 18-Fluoro-2-Deoxy-Glucose Positron Emission Tomography/Computed Tomography as Response and Prognosis Predictive Factor of Concurrent Chemoradiotherapy after Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Study. Šedienė S; Kulakienė I; Rudžianskas V; Ambrazienė R Medicina (Kaunas); 2018 May; 54(2):. PubMed ID: 30344262 [No Abstract] [Full Text] [Related]
34. Textural features in pre-treatment [F18]-FDG-PET/CT are correlated with risk of local recurrence and disease-specific survival in early stage NSCLC patients receiving primary stereotactic radiation therapy. Pyka T; Bundschuh RA; Andratschke N; Mayer B; Specht HM; Papp L; Zsótér N; Essler M Radiat Oncol; 2015 Apr; 10():100. PubMed ID: 25900186 [TBL] [Abstract][Full Text] [Related]
35. Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy. Dooms C; Verbeken E; Stroobants S; Vansteenkiste J J Thorac Oncol; 2009 Oct; 4(10):1221-5. PubMed ID: 19641474 [TBL] [Abstract][Full Text] [Related]
36. Xi M; Liao Z; Hofstetter WL; Komaki R; Ho L; Lin SH J Nucl Med; 2017 Nov; 58(11):1756-1763. PubMed ID: 28522744 [TBL] [Abstract][Full Text] [Related]
38. Luan X; Huang Y; Gao S; Sun X; Wang S; Ma L; Teng X; Lu H; Yu J; Yuan S Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2336-2342. PubMed ID: 27631310 [TBL] [Abstract][Full Text] [Related]
39. F-18-FDG-PET confined radiotherapy of locally advanced NSCLC with concomitant chemotherapy: results of the PET-PLAN pilot trial. Fleckenstein J; Hellwig D; Kremp S; Grgic A; Gröschel A; Kirsch CM; Nestle U; Rübe C Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e283-9. PubMed ID: 21470782 [TBL] [Abstract][Full Text] [Related]
40. Utility of fluorodeoxyglucose-positron emission tomography in the identification of new lesions in lung cancer patients for the assessment of therapy response. Obrzut S; Bykowski J; Badran K; Hayeri MR; Hoh CK Nucl Med Commun; 2010 Dec; 31(12):1008-15. PubMed ID: 20926977 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]